Brief: Acorda Therapeutics Provides Long-Term Business Plan And Financial Guidance
27/10/2022 12:56
Oct 27 (Reuters) - Acorda Therapeutics Inc ACOR.O :
* ACORDA THERAPEUTICS PROVIDES LONG-TERM BUSINESS PLAN AND
FINANCIAL GUIDANCE
* ACORDA THERAPEUTICS INC - EXPECTS TO BE CASH-FLOW POSITIVE
IN
2023
* ACORDA THERAPEUTICS INC SEES 2022 NET REVENUE $116.0 -
$119.7
MILLION
* ACORDA THERAPEUTICS INC SEES 2023 NET REVENUE $121.3 -
$134.3
MILLION
Source text for Eikon: ID:nBw22gDcWa
Further company coverage: ACOR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acorda Therapeutics
See all newsBrief: Acorda TherapeuticsCourt Held Hearing To Consider Approval Of Sale Of Substantially All Of Co's Assets To Merz Pharmaceuticals Under Asset Sale
Brief: Acorda Says Debtors Did Not Receive More Than One Qualified Bid Before Bid Deadline, In Connection With Chapter 11 Proceedings
Live Markets: Biotech companies in 'Darwinian' world as cash remains king
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease (updated)
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease